查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1996531

甲癬治療市場：2026-2032年全球市場預測（依藥物類型、活性成分、劑型、治療環境、年齡層、性別、疾病嚴重程度及分銷管道分類）

Onychomycosis Treatment Market by Drug Type, Active Ingredient, Formulation, Treatment Setting, Age Group, Gender, Disease Severity, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，甲癬治療市場價值將達到 22.9 億美元，到 2026 年將成長至 25.2 億美元，到 2032 年將達到 47 億美元，年複合成長率為 10.77%。

主要市場統計數據
基準年 2025 22.9億美元
預計年份：2026年 25.2億美元
預測年份 2032 47億美元
複合年成長率 (%) 10.77%

本報告總結了甲癬的當前臨床和商業性格局，指出了未滿足的需求、相關人員的趨勢以及不斷發展的治療途徑。

由於人口老化、合併症盛行率增加以及患者對治療耐受性和便利性的期望不斷變化，甲癬仍然是臨床和商業性持續面臨的挑戰。臨床醫生在診斷甲癬時面臨許多困難，因為其症狀不典型且病因複雜；而患者往往由於顧慮美觀或既往治療失敗而延誤就醫，導致巨大的未滿足醫療需求。

治療創新、製劑進步和醫療保健服務的演變如何重新定義甲癬的治療選擇、藥物依從性和商業化？

隨著治療方法的創新與不斷變化的患者期​​望和醫療服務模式相融合，甲癬的治療格局正在經歷一場變革。治療方法正從單一療法轉向綜合治療方法，結合外用藥物、口服藥物、醫療設備介入和支持性護理，以提高療效和病人依從性。這種多管齊下的策略正在重塑臨床醫生選擇輕症和重症甲癬治療方法的方式，以及製藥公司在臨床訊息中如何定位其產品的優勢。

評估美國關稅措施在 2025 年之前對供應鏈、採購和購買的影響，因為這些措施將重塑成本結構和商業化選擇。

美國計劃在2025年前實施新的關稅措施，將對皮膚科和抗真菌產品的供應鏈、籌資策略和定價動態連鎖反應。從海外採購活性成分、添加劑或成品的製造商正在重新審視其採購地點和合約條款，以降低進口關稅和清關相關的風險。這些調整往往會導致供應計劃的改變，進而可能影響分銷點的產品供應和庫存緩衝。

透過多方面的細分，我們旨在明確患者特徵、治療模式和分佈趨勢，從而為制定有針對性的臨床和商業策略做出貢獻。

詳細的市場細分揭示了臨床偏好、患者行為和分銷趨勢的輪廓，這些都指南產品開發和市場進入策略。無論藥物類型如何，治療方法的組合多種多樣，從聯合治療和雷射療法到口服和外用療法，每種療法都有其獨特的療效、安全性和依從性特徵，這些都會影響治療方法的治療方法通常與疾病的嚴重程度、合併症的負擔以及預期療效（無論是短期療效還是長期療效）密切相關。

本研究評估了美洲、歐洲、中東和非洲以及亞太地區的區域監管多樣性、醫療保健資金來源和分銷管道成熟度如何影響產品採用和獲取趨勢。

區域趨勢對塑造臨床實踐模式、監管通路和分銷基礎設施至關重要，進而影響產品的普及應用。在美洲，完善的臨床網路、廣泛的門診服務以及活躍的藥房管道，為創新型外用製劑和全身療法提供了良好的環境，使其能夠在可靠的安全性和療效對比證據的支持下，迅速滲透到臨床實踐中。報銷機制和支付方的審查往往側重於價值和真實世界的臨床結果，從而影響處方集制定和合約條款。

成熟新興企業之間的競爭定位，是由臨床差異化、製劑研發領先地位、策略聯盟和供應鏈韌性所驅動的。

甲癬領域的競爭格局圍繞著臨床差異化、製劑創新以及在真實臨床環境中證明療效持續性。成熟的新興企業主要企業憑藉豐富的臨床試驗經驗、深厚的監管知識以及與關鍵意見領袖 (KOL) 和支付方建立的良好關係，保持著競爭優勢。同時，小規模的專科製藥公司和生物技術參與企業致力於透過專注於製劑科學和新型作用機制，在細分市場中站穩腳跟。

為製造商和相關人員提供切實可行的策略方法，將證據產生、配方技術進步和供應鏈韌性相結合，以確保永續的競爭優勢。

產業領導企業應優先考慮協作方式，將臨床證據的取得、製劑創新和供應鏈緊急時應對計畫有機結合。儘早投資於直接對照試驗和真實世界研究，以評估治療效果的永續性、老年患者的安全性以及患者報告的療效，將有助於增強與支付方談判和與臨床醫生合作時的價值提案。同時，最佳化製劑以縮短療程並提高藥物對指甲的滲透性，將顯著提高患者的用藥依從性和滿意度，從而創造出引人入勝的商業性故事。

透過結合相關人員訪談、系統性文獻綜述和檢驗的嚴格混合方法研究設計，我們提供了可操作的臨床和商業性見解，同時清楚地指出了它們的局限性。

本研究途徑結合了對皮膚科醫生、藥劑師、供應鏈經理和支付方代表的結構化訪談，以及對監管申報文件、臨床試驗註冊資訊和同行評審文獻的廣泛二次分析。主要研究著重於半結構化訪談，以捕捉關於治療決策因素、未滿足的需求和營運挑戰的細微觀點，從而能夠與公開的臨床證據和政策文件進行定性檢驗。

本報告總結了臨床創新、供應鏈韌性和實證商業化對於甲癬治療持續進展的策略意義。

總之，甲癬仍然是一個臨床需求極高的領域，活性成分、製劑技術和綜合治療方法的進步正在重塑治療選擇。相關人員的成功需要權衡臨床療效、老年和合併症患者群體的安全性、不斷變化的銷售管道以及各地不同的法規等複雜因素。策略性地關注能夠證明治療效果持續、以患者為中心的便利性和明確的經濟價值的證據，對於確保臨床醫生採納和支付方支持至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：以藥物類型分類的甲癬治療市場

  • 聯合治療
  • 雷射療法
  • 口服療法
  • 局部治療

第9章：以活性成分分類的甲癬治療市場

  • 阿莫羅芬
  • 環吡羅
  • 依芬那康唑
  • Fluconazole
  • Itraconazole
  • 塔巴勃洛爾
  • Terbinafine

第10章：以劑型分類的甲癬治療市場

  • 奶油
  • 凝膠
  • 指甲油
  • 解決方案
  • 片劑和膠囊

第11章：依治療環境分類的甲癬治療市場

  • 居家照護
  • 住院治療
  • 門診治療

第12章：甲癬治療市場：依年齡層別分類

  • 18-65歲
  • 65歲或以上
  • 18歲以下

第13章：甲癬治療市場：性別

  • 女士
  • 男性

第14章：依疾病嚴重程度分類的甲癬治療市場

  • 輕度至中度
  • 復發
  • 嚴重

第15章：甲癬治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第16章：甲癬治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章：甲癬治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章：甲癬治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章：美國甲癬治療市場

第20章：中國甲癬治療市場

第21章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bausch Health Companies Inc.
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Galderma SA
  • Johnson & Johnson Services, Inc.
  • LEO Pharma A/S
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-FD3F12D54166

The Onychomycosis Treatment Market was valued at USD 2.29 billion in 2025 and is projected to grow to USD 2.52 billion in 2026, with a CAGR of 10.77%, reaching USD 4.70 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.29 billion
Estimated Year [2026] USD 2.52 billion
Forecast Year [2032] USD 4.70 billion
CAGR (%) 10.77%

Framing the modern clinical and commercial landscape of onychomycosis to illuminate unmet needs, stakeholder dynamics, and evolving treatment pathways

Onychomycosis presents a persistent clinical and commercial challenge driven by aging populations, increasing comorbidity prevalence, and evolving patient expectations for tolerability and convenience. Clinicians face diagnostic complexity due to atypical presentations and mixed etiologies, while patients often delay seeking care because of perceived cosmetic concerns and previous treatment failures, creating a landscape where unmet needs remain pronounced.

Recent advances in therapeutic modalities, including more targeted topical antifungals, innovations in oral agents, and adjunctive technologies like laser interventions, have diversified the care pathway and expanded options for different patient profiles. Nevertheless, gaps persist in adherence, long-term relapse prevention, and real-world effectiveness data. Payers and providers are converging on value-driven decision criteria, emphasizing safety profiles, treatment duration, and demonstrable improvements in patient-reported outcomes.

This introduction synthesizes the clinical context, stakeholder dynamics, and the shifting treatment paradigm while setting the stage for deeper exploration of regulatory, economic, and commercial forces that shape product development, market access strategies, and competitive positioning in onychomycosis care.

How therapeutic innovation, formulation advances, and care delivery evolution are redefining treatment choice, adherence, and commercialization in onychomycosis care

The onychomycosis landscape is undergoing transformative shifts as therapeutic innovation intersects with changing patient expectations and delivery models. Treatment approaches are moving beyond single-modality prescriptions toward integrated regimens that combine topical agents, oral therapies, device-based interventions, and supportive measures to improve efficacy and adherence. This multidimensional strategy reframes how clinicians select treatments for mild versus severe disease and how manufacturers position product benefits in clinical messaging.

Simultaneously, investment in formulation science has elevated the role of penetration enhancers, novel vehicle systems, and application convenience, which together address long-standing barriers such as slow nail penetration and prolonged treatment durations. Emerging active ingredients and combination strategies are being tested to reduce relapse rates and improve cure durability, while safety and drug-drug interaction profiles remain central to adoption in populations with polypharmacy, particularly older adults.

On the delivery front, digital channels and telehealth services are reshaping patient access and follow-up, enabling earlier intervention and improved adherence monitoring. Pharmacy models are adapting to this shift, with online pharmacies and home care pathways gaining traction alongside traditional hospital and retail channels. These transformative trends create both opportunities for differentiated clinical value and challenges for market entry, necessitating integrated commercialization plans that account for regulatory nuance, payer expectations, and patient-centric positioning.

Assessing the supply chain, sourcing, and procurement consequences of United States tariff measures through 2025 that are reshaping cost structures and commercialization choices

The introduction of new tariff measures in the United States through 2025 has created a ripple effect across supply chains, procurement strategies, and pricing dynamics for dermatology and antifungal products. Manufacturers that source active pharmaceutical ingredients, excipients, or finished goods internationally are reassessing sourcing footprints and contractual terms to mitigate import duties and customs-related timeline risks. These adjustments often translate into supply planning changes that can affect product availability and inventory buffers at distribution points.

Short-term responses have included shifting component sourcing to domestic or low-tariff jurisdictions, renegotiating supplier agreements to include tariff-sharing clauses, and selectively increasing onshore inventory for critical SKUs. Over time, firms are evaluating nearshore manufacturing and localized formulation facilities as structural responses to tariff-driven cost pressures. These strategic investments reduce exposure to trade volatility but require capital allocation decisions that influence product launch timetables and margin structures.

Payers and procurement teams are also reacting by tightening contracting terms, emphasizing value-based arrangements, and scrutinizing total cost of therapy. Clinical leaders and purchasing departments may favor therapeutics with differentiated safety or adherence advantages that justify adjusted pricing in light of increased supply costs. The net effect is a heightened premium on supply chain resilience, commercial flexibility, and the capacity to communicate clear value propositions that absorb the operational impacts of tariff-driven cost changes without undermining access or clinician trust.

Illuminating patient profiles, therapeutic formats, and distribution dynamics through multi-dimensional segmentation to inform targeted clinical and commercial strategies

Detailed segmentation reveals the contours of clinical preference, patient behavior, and distribution dynamics that inform product development and go-to-market strategies. Across drug type, the therapeutic mix ranges from combination therapy and laser therapy to oral therapy and topical therapy, with each modality carrying distinct efficacy, safety, and adherence profiles that influence clinician selection and patient acceptance. Treatment choice often correlates with disease severity, comorbidity burden, and the desire for rapid versus sustained outcomes.

Considering active ingredient differentiation, compounds such as amorolfine, ciclopirox, efinaconazole, fluconazole, itraconazole, tavaborole, and terbinafine exhibit varied mechanisms of action, pharmacokinetics, and safety considerations. These differences dictate labeling, contraindications, and monitoring needs, and they provide the basis for clinical positioning against competing therapies. Formulation matters as well: cream, gel, nail lacquer, solution, and tablet capsule formats change the patient experience, affect adherence, and present unique manufacturing and regulatory considerations.

Distribution channel analysis highlights the role of hospital pharmacy, online pharmacy, and retail pharmacy pathways in determining access, counseling opportunities, and point-of-sale dynamics. Treatment setting segmentation across home care, hospital inpatient, and outpatient clinic environments further guides how therapies are administered and supported, with implications for follow-up, adherence interventions, and reimbursement. Age group distinctions-18 to 65 years, above 65 years, and below 18 years-intersect with gender segments of female and male patients to shape epidemiologic trends and address age- or gender-specific safety concerns. Finally, disease severity categories of mild to moderate, recurrent, and severe act as primary drivers of therapeutic intensity and regimen selection. Synthesizing these segmentation layers allows stakeholders to identify target patient cohorts, tailor messaging, and prioritize clinical evidence generation that resonates with prescribers and payers alike.

Evaluating how regional regulatory diversity, healthcare financing, and channel maturity across the Americas, EMEA, and Asia-Pacific shape adoption and access dynamics

Regional dynamics are pivotal in shaping clinical practice patterns, regulatory pathways, and distribution infrastructures that affect product adoption. In the Americas, established clinical networks, broad outpatient access, and active pharmacy channels create an environment where both innovative topical formulations and systemic therapies can achieve rapid clinical uptake when supported by robust safety and comparative-effectiveness evidence. Reimbursement mechanisms and payer scrutiny tend to emphasize value and real-world outcomes, influencing formulary decisions and contracting approaches.

In Europe, Middle East & Africa, diverse regulatory frameworks and heterogeneous healthcare financing models mean that market entry and adoption trajectories vary significantly across jurisdictions. Centralized regulatory pathways coexist with localized reimbursement negotiations, requiring tailored launch strategies and region-specific evidence packages. Distribution models in this region range from hospital-centric procurement in some markets to thriving retail and online pharmacy ecosystems in others, affecting channel prioritization.

The Asia-Pacific region is characterized by a mix of high-volume patient populations, evolving clinical guidelines, and rapidly modernizing healthcare infrastructures. Local manufacturing capabilities, regulatory acceleration pathways in select markets, and growing telehealth penetration influence how therapies are evaluated and adopted. Across regions, cultural perceptions of dermatologic conditions, access to specialist care, and the maturity of pharmacy channels collectively determine patient engagement, diagnostic timeliness, and long-term management approaches. Understanding these regional nuances is essential for calibrating clinical development, regulatory submissions, and commercial deployment.

Competitive positioning driven by clinical differentiation, formulation leadership, strategic alliances, and supply chain resilience among established and emerging players

Competitive dynamics among leading and emerging companies in onychomycosis are centered on clinical differentiation, formulation innovation, and the ability to demonstrate durable outcomes in real-world settings. Established pharmaceutical developers maintain advantages through broad clinical trial experience, extensive regulatory knowledge, and existing relationships with key opinion leaders and payer bodies. At the same time, smaller specialty firms and biotech entrants are leveraging targeted approaches to formulation science and novel mechanisms of action to carve niche positions.

Strategic activity includes focused R&D investment in penetration enhancers and combination regimens, alliances with device manufacturers for adjunctive therapies, and partnerships that accelerate access to specialty pharmacy and digital adherence tools. Licensing agreements and regional distribution partnerships are common maneuvers to extend geographic reach while minimizing direct infrastructure investment. Additionally, companies are prioritizing the generation of patient-reported outcomes and health-economic evidence to support reimbursement discussions and to differentiate in crowded therapy classes.

Operational readiness-manufacturing scalability, quality control, and supply chain resilience-remains a critical competitive lever, especially as firms navigate tariff and procurement headwinds. Companies that integrate clinical differentiation with robust commercialization models and responsive distribution strategies are positioned to secure clinician trust and payer support, while maintaining flexibility to pivot as evidence or regulatory landscapes evolve.

Practical strategic initiatives for manufacturers and stakeholders to align evidence generation, formulation advances, and supply chain resilience for sustained competitive advantage

Industry leaders should prioritize a coordinated approach that aligns clinical evidence generation, formulation innovation, and supply chain contingency planning. Early investments in head-to-head and real-world studies that capture durability of response, safety in older adults, and patient-reported outcomes will strengthen value propositions during payer negotiations and clinician engagement. Concurrently, optimizing formulations to reduce treatment duration and enhance nail penetration can materially improve adherence and patient satisfaction, creating a compelling commercial narrative.

On the operational front, diversifying sourcing strategies, exploring nearshore manufacturing options, and implementing tariff-mitigation clauses with suppliers will reduce exposure to trade volatility and support stable supply. Commercial teams must also cultivate channel-specific strategies that reflect the nuances of hospital pharmacy, online pharmacy, and retail pharmacy operations, while ensuring that patient support programs and digital adherence tools are integrated into launch plans.

Finally, leaders should pursue selective partnerships with device innovators, digital health providers, and regional distributors to accelerate access in priority markets. These combined actions-evidence-focused clinical programs, formulation differentiation, resilient sourcing, and strategic alliances-will enable organizations to capture clinical credibility, manage cost pressures, and deliver patient-centered solutions that stand out in a competitive therapeutic area.

A rigorous mixed-methods research design combining stakeholder interviews, systematic literature review, and triangulation to provide actionable clinical and commercial insights with transparent limitations

The research approach combined structured primary engagement with dermatology clinicians, pharmacists, supply chain managers, and payer representatives alongside extensive secondary analysis of regulatory filings, clinical trial registries, and peer-reviewed literature. Primary research prioritized semi-structured interviews to capture nuanced perspectives on treatment decision drivers, unmet clinical needs, and operational challenges, enabling qualitative triangulation with publicly available clinical evidence and policy documents.

Secondary research involved systematic review of published clinical trials, safety reports, and formulation studies to validate mechanistic claims and comparative tolerability profiles. Data synthesis emphasized evidence quality, methodological transparency, and relevance to real-world clinical practice. Triangulation techniques were applied to reconcile differing stakeholder viewpoints and to identify consensus areas as well as evidence gaps that warrant further study.

Quality assurance measures included independent review of data extraction, standardized interview protocols to reduce bias, and documentation of limitations such as regional heterogeneity in clinical practice and variability in long-term outcome reporting. The methodology was designed to foreground actionable insights while acknowledging areas where additional primary data collection or longer-term observational studies would strengthen confidence in specific clinical or economic conclusions.

Summarizing the strategic implications of clinical innovation, supply chain resilience, and evidence-driven commercialization for sustained progress in onychomycosis care

In conclusion, onychomycosis remains an area of high clinical need where advances in active ingredients, formulation technologies, and integrated treatment approaches are reshaping therapeutic choices. Stakeholders must navigate a complex interplay of clinical efficacy, safety considerations in older and comorbid populations, distribution channel evolution, and regional regulatory diversity to succeed. Strategic emphasis on evidence that demonstrates durable outcomes, patient-centered convenience, and clear economic value will be decisive in securing clinician adoption and payer support.

Operational resilience-particularly in supply chain sourcing and tariff mitigation-will influence product availability and commercial robustness as geopolitical and trade factors continue to evolve. Companies that combine clinical differentiation with pragmatic commercialization plans, targeted regional strategies, and partnerships to enhance access will be best positioned to address unmet needs and build lasting therapeutic franchises. Continued investment in real-world evidence and patient engagement will remain central to translating innovation into meaningful improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Onychomycosis Treatment Market, by Drug Type

  • 8.1. Combination Therapy
  • 8.2. Laser Therapy
  • 8.3. Oral Therapy
  • 8.4. Topical Therapy

9. Onychomycosis Treatment Market, by Active Ingredient

  • 9.1. Amorolfine
  • 9.2. Ciclopirox
  • 9.3. Efinaconazole
  • 9.4. Fluconazole
  • 9.5. Itraconazole
  • 9.6. Tavaborole
  • 9.7. Terbinafine

10. Onychomycosis Treatment Market, by Formulation

  • 10.1. Cream
  • 10.2. Gel
  • 10.3. Nail Lacquer
  • 10.4. Solution
  • 10.5. Tablet Capsule

11. Onychomycosis Treatment Market, by Treatment Setting

  • 11.1. Home Care
  • 11.2. Hospital Inpatient
  • 11.3. Outpatient Clinic

12. Onychomycosis Treatment Market, by Age Group

  • 12.1. 18 To 65 Years
  • 12.2. Above 65 Years
  • 12.3. Below 18 Years

13. Onychomycosis Treatment Market, by Gender

  • 13.1. Female
  • 13.2. Male

14. Onychomycosis Treatment Market, by Disease Severity

  • 14.1. Mild To Moderate
  • 14.2. Recurrent
  • 14.3. Severe

15. Onychomycosis Treatment Market, by Distribution Channel

  • 15.1. Hospital Pharmacy
  • 15.2. Online Pharmacy
  • 15.3. Retail Pharmacy

16. Onychomycosis Treatment Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Onychomycosis Treatment Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Onychomycosis Treatment Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Onychomycosis Treatment Market

20. China Onychomycosis Treatment Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. Bausch Health Companies Inc.
  • 21.6. Bayer AG
  • 21.7. Dr. Reddy's Laboratories Ltd.
  • 21.8. Galderma S.A.
  • 21.9. Johnson & Johnson Services, Inc.
  • 21.10. LEO Pharma A/S
  • 21.11. Novartis AG
  • 21.12. Pfizer Inc.
  • 21.13. Sanofi S.A.
  • 21.14. Sun Pharmaceutical Industries Ltd.
  • 21.15. Teva Pharmaceutical Industries Ltd.
  • 21.16. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 222. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)